Transforming the field of immune tolerance with a novel antigen-specific and targeted nanoparticle technology
About us
Topas Therapeutics is a clinical-stage biotechnology company with a mission to deliver novel, disease-modifying treatments for autoimmune and inflammatory diseases. At Topas we are developing a proprietary platform of antigen-specific nanoparticle conjugates uniquely positioned to address major unmet need in T-cell mediated diseases in a targeted manner.
The Challenge
Current treatment of autoimmune and inflammatory diseases relies on symptomatic relief, with limited disease-modifying effects, and considerable risk of immune suppression.
Treatment of autoimmune diseases has relied on the use of broad immunosuppressant agents that, while delivering symptomatic relief, are not targeted to the underlying molecular mechanism. Therefore, they lack disease-modifying effects. Available therapies have significant long-term side effects, and, because of their untargeted and immunosuppressive nature, they interfere with defense mechanisms necessary to fight pathogens and malignancies. Targeting the loss of tolerance to self- or immunogenic antigens, which is the cause of autoimmune antigen-driven diseases, represents a paradigm shift in the treatment of those diseases.
TOPAS Solution
Our nanoparticle technology represents a paradigm shift compared to current immunotherapies that broadly modulate or suppress the immune response.

Topas’ antigen-specific proprietary nanoparticle technology leverages the natural tolerogenic power of the liver. Topas nanoparticle conjugates (TPC) are designed for targeted delivery into the liver sinusoidal endothelial cells (LSECs), leading to antigen-specific tolerance, fast and rapid clearance from circulation and avoiding undesired systemic and immune reactions.
Events
BIO-Europe 2023
November 06–08, 2023: in person
Contact:
Mireia Gómez-Angelats, PhD
Chief Business Officer
info@topas-therapeutics.com